ArticleAntioxidants (Basel, Switzerland)2026
Allomyrinasin, an Edible Insect-Derived Peptide, Ameliorates High-Fat Diet-Induced Hepatic Oxidative Stress and Metabolic Dysfunction.
Article in Antioxidants (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effects ofBiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Allomyrinasin is an antimicrobial peptide derived from the larvae of the edible insect Allomyrina dichotoma and has been reported to exert anti-inflammatory activity, although its role in metabolic regulation remains unclear. This study aimed to investigate the metabolic and hepatoprotective effects of allomyrinasin in a high-fat diet (HFD)-induced obese mouse model. Male C57BL/6J mice were fed an HFD for 6 weeks to induce body weight gain and hyperglycemia, followed by 10 weeks of oral administration of allomyrinasin (0.1 mg/kg/day) under continued HFD conditions, with metformin used as a positive control. Metabolic parameters related to glucose homeostasis, insulin sensitivity, lipid metabolism, hepatic injury, oxidative stress, inflammation, and fibrotic responses were evaluated. Allomyrinasin significantly attenuated HFD-associated body weight gain and improved glucose tolerance and insulin sensitivity. These effects were accompanied by favorable modulation of serum lipid profiles and suppression of hepatic lipogenic signaling, including reduced expression of key regulators of de novo lipogenesis. In parallel, allomyrinasin mitigated hepatic inflammatory, fibrotic, and oxidative stress-related alterations, as reflected by improvements in biochemical markers and molecular analyses. Collectively, these findings indicate that allomyrinasin contributes to the improvement of metabolic regulation and hepatic homeostasis in HFD-fed mice. Our results support allomyrinasin as a promising food-applicable bioactive peptide and potential functional ingredient for the prevention or management of obesity-related metabolic disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.